ENDRA Reports Q4/FY25 Results: $762K Cash on Hand Amid Strategic Review
Summary
ENDRA Life Sciences reported its fourth quarter and full-year 2025 financial results, showing a net loss of $7.0 million for the year, an improvement from $11.5 million in 2024, primarily due to reduced operating expenses. However, the company ended 2025 with a critically low cash balance of $762,000, supplemented by $2.0 million in digital assets. This financial update comes as the company reiterates its ongoing evaluation of strategic alternatives, a process announced on March 25, 2026, to maximize shareholder value. The low cash position is highly material for a company with a market capitalization of approximately $5.4 million, raising significant concerns about its short-term liquidity and ability to fund operations. Traders will be closely watching for updates on the strategic review and any potential financing activities.
At the time of this announcement, NDRA was trading at $4.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $2.90 to $11.96. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.